SCHEMBL14645356

SCHEMBL14645356

O=C(O)Cc1cc(-c2cccs2)sc1-c1ccc(-c2sc(-c3ccc(C(=O)O)s3)cc2CC(=O)O)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
KDM4E B2RXH2 5/20 0.48
LMNA P02545 2/20 0.48
GAA P10253 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MAPT P10636 2/20 0.48
GLA P06280 1/20 0.48
RAB9A P51151 4/20 0.47
NPC1 O15118 4/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
POLB P06746 2/20 0.47
TP53 P04637 1/20 0.47
NFKB1 P19838 1/20 0.47
MAPK1 P28482 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
NFKB2 Q00653 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15695250 0.93 ALDH1A1 (0.45) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL15695254 0.93 ALDH1A1 (0.45) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL15695323 0.93 ALDH1A1 (0.45) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL15695316 0.93 ALDH1A1 (0.45) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL14646202 0.92 DPP4 (0.45) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL9976552 0.91 ALDH1A1 (0.45) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL14646131 0.90 POLB (0.41) ALDH1A1KDM4EGAAGLARAB9A
SCHEMBL14646273 0.90 POLB (0.41) ALDH1A1KDM4EGAAGLARAB9A
SCHEMBL14645296 0.90 POLB (0.41) ALDH1A1KDM4EGAAGLARAB9A
SCHEMBL9976532 0.90 POLB (0.41) ALDH1A1KDM4EGAAGLARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 US disclosed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 US disclosed
EP-2817304-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BioChromix NewCo AB (SE) 2014-12-31 EP disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 US disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PRNP, TBCA, HSPA5 ALDH1A1 1466/4885KDM4E 4549/4885LMNA 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.